Drugs / Sym024
last change Nov 2024 re-read 2 minutes ago

Sym024

Developed for
metastatic malignant neoplasm
Investigated by
Symphogen A/S

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04672434 Nov 2020 → Nov 2024 metastatic malignant neoplasm Symphogen A/S Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Sym024 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04672434